BACKGROUND: High-dose ketoconazole (HDK) in combination with steroids has been recognized as an effective secondary hormonal therapy in androgen-independent prostate cancer (AIPC). However, HDK causes more severe adverse events than low-dose ketoconazole (LDK). To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC. METHODS: In a single institution, patients with AIPC treated with LDK (at a dose of 200 mg orally 3 times daily) as secondary hormonal therapy with or without concomitant steroids were retrospectively identified. In addition, patients were identified who received dose escalation to HDK (400 mg orally 3 times daily) after experiencing a rising prostate-specific antigen (PSA) level. RESULTS: Thirty-nine of 138 eligible patients (28.3%, 95% confidence interval [95% CI], 20.9-36.6%) treated with LDK experienced PSA declines > or =50%. The median time to disease progression or dose escalation on LDK was 3.2 months (range, 0.1(+)-61 months). Dose escalation to HDK was subsequently performed in 55 patients (39.9%), 7 of whom (12.7%) demonstrated a subsequent PSA decline > or =50%. A longer duration of primary androgen deprivation therapy and total duration of all previous hormonal therapies was associated with a longer time to progression with LDK (P < .05). The most common reversible adverse effect of LDK was NCI Common Toxicity Criteria Grade 1 or 2 fatigue (12.3%). CONCLUSIONS: LDK is associated with a PSA response rate comparable to HDK as secondary hormonal therapy in patients with AIPC, but with less toxicity. Although uncommon, additional durable responses occurred in some patients after dose escalation.
BACKGROUND: High-dose ketoconazole (HDK) in combination with steroids has been recognized as an effective secondary hormonal therapy in androgen-independent prostate cancer (AIPC). However, HDK causes more severe adverse events than low-dose ketoconazole (LDK). To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC. METHODS: In a single institution, patients with AIPC treated with LDK (at a dose of 200 mg orally 3 times daily) as secondary hormonal therapy with or without concomitant steroids were retrospectively identified. In addition, patients were identified who received dose escalation to HDK (400 mg orally 3 times daily) after experiencing a rising prostate-specific antigen (PSA) level. RESULTS: Thirty-nine of 138 eligible patients (28.3%, 95% confidence interval [95% CI], 20.9-36.6%) treated with LDK experienced PSA declines > or =50%. The median time to disease progression or dose escalation on LDK was 3.2 months (range, 0.1(+)-61 months). Dose escalation to HDK was subsequently performed in 55 patients (39.9%), 7 of whom (12.7%) demonstrated a subsequent PSA decline > or =50%. A longer duration of primary androgen deprivation therapy and total duration of all previous hormonal therapies was associated with a longer time to progression with LDK (P < .05). The most common reversible adverse effect of LDK was NCI Common Toxicity Criteria Grade 1 or 2 fatigue (12.3%). CONCLUSIONS: LDK is associated with a PSA response rate comparable to HDK as secondary hormonal therapy in patients with AIPC, but with less toxicity. Although uncommon, additional durable responses occurred in some patients after dose escalation.
Authors: Andrew J Roth; Christian Nelson; Barry Rosenfeld; Howard Scher; Susan Slovin; Michael Morris; Noelle O'Shea; Gabrielle Arauz; William Breitbart Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: Ethan Basch; D Andrew Loblaw; Thomas K Oliver; Michael Carducci; Ronald C Chen; James N Frame; Kristina Garrels; Sebastien Hotte; Michael W Kattan; Derek Raghavan; Fred Saad; Mary-Ellen Taplin; Cindy Walker-Dilks; James Williams; Eric Winquist; Charles L Bennett; Ted Wootton; R Bryan Rumble; Stacie B Dusetzina; Katherine S Virgo Journal: J Clin Oncol Date: 2014-09-08 Impact factor: 44.544
Authors: Joaquim Bellmunt; Thian Kheoh; Margaret K Yu; Matthew R Smith; Eric J Small; Peter F A Mulders; Karim Fizazi; Dana E Rathkopf; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Ian D Davis; Dirk Schrijvers; Andrew Protheroe; Arturo Molina; Peter De Porre; Thomas W Griffin; Johann S de Bono; Charles J Ryan; Stéphane Oudard Journal: Eur Urol Date: 2015-10-24 Impact factor: 20.096
Authors: E N Lo; L A Beckett; C X Pan; D Robles; J M Suga; J M Sands; P N Lara Journal: Prostate Cancer Prostatic Dis Date: 2015-02-10 Impact factor: 5.554